OAM
LKFT

Oxford Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Oxford Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,479
Closed -$300K – 1554
2017
Q1 		$300K Buy
+3,479
New +$251K 0.01% 1201

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Oxford Asset Management's LKFT Position: Q2 2017 in Review

Oxford Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2017, closing a stake of 3,479 shares — an estimated $300K sold.

Oxford Asset Management first reported a position in LKFT in Q1 2017 and held it in 1 quarter. The position peaked at $300K in Q1 2017. 78 funds tracked by Wall St. Rank hold LKFT as of Q2 2017.

  • Oxford Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2017 after selling out during the quarter.
  • Oxford Asset Management sold 3,479 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2017, an estimated $300K.
  • Oxford Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2017 and held it in 1 quarter.
  • Oxford Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $300K in Q1 2017.
  • 78 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2017.

Based on Oxford Asset Management's 13F filing for Q2 2017, filed 11 Aug 2017.